Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

• ClinicalTrials.gov Identifier: NCT04232657
• Recruitment Status: Recruiting
• First Posted: January 18, 2020
• Last Update Posted: March 27, 2023
• Sponsor: VA Office of Research and Development
• Collaborator: Kessler Institute for Rehabilitation
• Information provided by (Responsible Party): VA Office of Research and Development

Study Description

Brief Summary:

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).

The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.

Condition or disease	Intervention/treatment	Phase
Spinal Cord Injury (=3 Years); Sublesional Bone Loss Secondary to SCI	Drug: Romosozumab; Drug: Denosumab; Drug: Placebo	Phase 2

Detailed Description:

Persons with chronic spinal cord injury (SCI) have markedly reduced bone mass and the loss of skeletal architectural integrity, which predisposes them to low-impact fractures. Currently, there is no practical treatment to reverse the severe bone loss in persons with chronic SCI. In the proposed study, a dual pharmacological intervention will be tested to improve bone health. Restoration of bone mass below the level of injury would be expected to reduce the morbidity associated with fractures and permit safer participation in upright activities. Quality of life would be substantially improved because of the ability to engage more securely in activities of daily living and to integrate into the community. Despite the depressed skeletal activity below the level of lesion in persons with chronic SCI, net bone loss occurs because resorption exceeds formation, with a difference between these rates in those with SCI being greater than that observed in the able-bodied population. Thus, it would be anticipated to be of value in persons with chronic SCI to increase bone turnover with the objective to increase bone formation over that of bone resorption. In a preclinical study that administered an anti-sclerostin antibody to rats 12 weeks after complete spinal cord transection bone, mineral density (BMD) was almost fully restored at the distal femoral metaphysis, with improved bone structure, and mechanical strength; in contrast, vehicle-treated animals after complete spinal transection had a marked reduction in distal femoral metaphysis BMD and a deterioration in bone structure and mechanical strength. When used to treat postmenopausal osteoporosis, romosozumab, a human monoclonal anti-sclerostin antibody, was more effective to increase bone mineral density (BMD) and to reduce fracture than any other anti-resorptive or bone-anabolic agent, and this effect was also evident for the appendicular skeleton, which is the site in individuals with chronic SCI of greatest bone loss and most frequent fracture. Because of the absence of clinical options available for the treatment of osteoporosis in individuals with chronic paralysis, the investigators have proposed to test an antagonist of sclerostin, which is a potent bone anabolic agent with proven efficacy in treating women with postmenopausal osteoporosis, to improve bone mass and reduce fragility fractures.

Thirty-nine male and female subjects with chronic, motor-complete or incomplete SCI (>3 post injury, American Spinal Injury Association Impairment Scale A & B) between the ages of 18 and 55 years old who have aBMD at the distal femur at the distal femur <1.0 g/cm2 will be recruited for participation in a randomized, double-blind, placebo-controlled, parallel group clinical trial. The outcome measures of the proposed study are bone mineral density (BMD) by peripheral quantitative computed tomography (pQCT) and dual energy x-ray absorptiometry (DXA), and biochemical markers of bone resorption and formation. This prospective, randomized, placebo controlled clinical trial will take place at the James J. Peters VA Medical Center (JJPVAMC) and Kessler Institute for Rehabilitation (KIR) (each facility will perform patient enrollment and study procedures).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 39 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized, double-blind, placebo-controlled, parallel group clinical trial
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Masking Description: Participants and study investigators / team members will be blinded to the treatment group assignment. The designated study drug administrator will be the only individual unblinded. This individual will administer the drug/placebo saline injections behind a sheet.
• Primary Purpose: Prevention
• Official Title: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
• Actual Study Start Date: October 28, 2020
• Estimated Primary Completion Date: February 1, 2024
• Estimated Study Completion Date: August 1, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Romosozumab Treatment (baseline to month 11); Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.	Drug: Romosozumab; 39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.; Other Name: Evenity
Placebo Comparator: Placebo (baseline to month 12); Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.	Drug: Placebo; Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).; Other Name: Normal Saline (NS) injection
Active Comparator: Denosumab (month 12 to month 24); Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).	Drug: Denosumab; Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.; Other Name: Prolia

Outcome Measures

Primary Outcome Measures :

1. Change in vBMD at the Distal Femur, measured by pQCT after 12 months of romosozumab treatment [ Time Frame: Baseline (0), Month 6, Month 12 ]
   Percent change of volumetric BMD (vBMD) (mg/cm^3)at the distal femur, measured by peripheral quantitative computed tomography (pQCT) (slice thickness 2.4mm, default voxel size of 0.5mm), with 12 months of romosozumab therapy. vBMD measurements will be taken at baseline, month 6 and month 12.
2. Change in vBMD at the distal femur after an additional 12 months of denosumab treatment [ Time Frame: Month 18, Month 24 ]
   Percent change of Integral vBMD (mg/cm^3)at the distal femur, measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm), after additional 12 months of denosumab therapy. vBMD measurements will be taken by pQCT at months 18 and 24.

Other Outcome Measures:

1. Additional variables by pQCT - vBMD Proximal Tibia [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change in proximal tibia vBMD (mg/cm^3), measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24.
2. Additional variables by pQCT - tBMD Distal Femur [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change in distal femur trabecular BMD (tBMD) (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24.
3. Additional variables by pQCT - tBMD Proximal Tibia [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change in proximal tibia tBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24.
4. Additional variables by pQCT - cortical BMD of the tibia (38% of the tibial length) [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change in cortical vBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24.
5. Additional variables by pQCT - Distal Tibia Microarchitecture [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular microarchitecture [trabecular separation (Tb.Sp), bone volume fraction (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th)] at baseline, month 6, month 12, month 18, and month 24.
6. Additional variables by DXA - aBMD Distal Femur and Proximal Tibia (i.e. knee) [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change of regional BMD of the knee (e.g., distal femoral and proximal tibial epiphyses using the orthopedic knee software commercially available from GE Lunar). The starting point to acquire the knee is set on the tibia approximately 10 cm distal from the edge of the patella, with the scan field extending to the epiphysis and metaphysis of the distal femur. aBMD measurements will be taken at Baseline (0), Month 6, Month 12, Month 18, Month 24.
7. Additional variables by DXA - aBMD Hip [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
   Percent change in aBMD of the hips (total dual dip and subregions) will be measured at Baseline (0), Month 6, Month 12, Month 18, Month 24. Accepted values for T-score and Z-scores of the hip will be utilized.
8. Biomarkers for Bone Resorption (CTx) [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
   Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Levels of serum C-telopeptide (CTx) (ABclonal. 86 Cummings Park, Woburn, MA) will be measured as the biomarker of bone resorption.
9. Biomarkers for Bone Formation (osteocalcin, alkaline phosphatase, P1NP) [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
   Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Serum osteocalcin (Alpco Diagnostics, Salem, NH), bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) and propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) will be measured as biomarkers of bone formation.
10. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    Serum total and ionized calcium concentration, 24-hour urine calcium, 25 OH-vitamin D level (DiaSorin Inc. Stillwater, MN), 1,25 (OH)2-vitamin D level (Quest Diagnostics), and intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured.The serum 25 OH-vitamin D level will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. Serum total and ionized calcium concentrations will be measured at baseline, 1, 3 months, and at 6-month intervals until month 24.
11. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum thyroid function (T3, T4, & TSH; DiaSorin Inc. Stillwater, MN) will be determined by kit assay.
12. Additional variables by pQCT - Distal Tibia Microarchitecture [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
    Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to bone volume fraction (BV/TV)at baseline, month 6, month 12, month 18, and month 24.
13. Additional variables by pQCT - Distal Tibia Microarchitecture [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
    Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular number (Tb.N) at baseline, month 6, month 12, month 18, and month 24.
14. Additional variables by pQCT - Distal Tibia Microarchitecture [ Time Frame: Baseline (0), Month 6, Month 12, Month 18, Month 24 ]
    Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular thickness (Tb.Th)at baseline, month 6, month 12, month 18, and month 24.
15. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    Serum ionized calcium concentration will be measured at baseline, months 1, 3, 6, 12, 18, and 24.
16. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    24-hour urine calcium will be measured at baseline, months 1, 3, 6, 12, 18, and 24.
17. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    25 OH-vitamin D levels (DiaSorin Inc. Stillwater, MN) will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated.
18. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    1,25 (OH)2-vitamin D level (Quest Diagnostics), will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated.
19. Calcium Metabolism Studies [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    Intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured at Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
20. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum cortisol will be measured by kit assay (MP Biomedicals, Orangeburg, NY).
21. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum total testosterone (T) will be determined by kit assay (MP Biomedicals, Orangeburg, NY).
22. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum free testosterone (calculated from total T, albumin and SHBG) will be measured by kit assay (MP Biomedicals, Orangeburg, NY).
23. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum estradiol (E2) will be measured by kit assay (MP Biomedicals, Orangeburg, NY).
24. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum growth hormone (GH) will be measured by kit assay (MP Biomedicals, Orangeburg, NY).
25. General Endocrine Studies [ Time Frame: Baseline (0), Month 12, Month 24 ]
    Serum insulin-like growth factor-1 (IGF-I) will be measured by kit assay (ALPCO Diagnostics, Salem, NH).
26. Biomarkers for Bone Formation [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    Change in levels of bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24.
27. Biomarkers for Bone Formation [ Time Frame: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 ]
    Change in levels of propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Motor-complete or incomplete SCI [C4 and below [upper motor lesions as determined by the International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale]; ISNCSCI score A-C
• Duration of injury >3 years
• Males and females (premenopausal) between the ages of 18 and 55 years old (the upper age limit is to reduce the influence of age on the ability of the skeleton to respond to pharmacologic stimulation)
• aBMD at the distal femur <1.0 g/cm2 (determined at screening)

Exclusion Criteria:

• Long-bone fracture of the leg within the past year
• History of prior bone disease (Paget's hyperparathyroidism, osteoporosis, etc.)
• Active and/or history of coronary heart disease or stroke within the past year
• Postmenopausal women
• Men with known hypogonadism prior to SCI
• Anabolic therapy longer than six months duration after SCI
• Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute SCI
• Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
• Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
• Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
• Chronic alcohol abuse
• Hypocalcemia
• Pregnancy
• Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
• Electrical stimulation of the lower extremities
• Current diagnosis of cancer or history of cancer
• Osteosarcoma
• Life expectancy less than 5 years

Contacts and Locations

Contacts

Contact: Jennifer Hong, BS; (718) 584-9000 ext 2113; jennifer.hong6@va.gov

Contact: Christopher Cardozo, MD; (718) 584-9000 ext 1828; Christopher.Cardozo@va.gov

Locations

United States, New Jersey

Kessler Institute for Rehabilitation; Recruiting

West Orange, New Jersey, United States, 07052

Contact: Christopher M Cirnigliaro, MS 973-731-3900 ext 1-2755 christopher.cirnigliaro@va.gov

Contact: Gregory T Cross, MS 9737313900 ext 1-2755 Gregory.Cross1@va.gov

United States, New York

James J. Peters VA Medical Center, Bronx, NY; Recruiting

Bronx, New York, United States, 10468-3904

Contact: Christopher Cardozo, MD 718-584-9000 ext 1828 Christopher.Cardozo@va.gov

Contact: Jennifer Hong, BS (718) 584-9000 ext 2113 jennifer.hong6@va.gov

Principal Investigator: Christopher Cardozo, MD

Sponsors and Collaborators

VA Office of Research and Development

Kessler Institute for Rehabilitation

Investigators

• Principal Investigator: Christopher Cardozo, MD; James J. Peters Veterans Affairs Medical Center

More Information

• Responsible Party: VA Office of Research and Development
• ClinicalTrials.gov Identifier: NCT04232657
• Other Study ID Numbers: B3415-R; BAU-19-66 ( Other Identifier: JJP VAMC Local IRB )
• First Posted: January 18, 2020
• Last Update Posted: March 27, 2023
• Last Verified: March 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: There is not a plan to make IPD available.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by VA Office of Research and Development:

Spinal Cord Injury; Veterans Affairs RR&D; Sublesional Bone Loss

Additional relevant MeSH terms:

Spinal Cord Injuries; Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System; Wounds and Injuries; Denosumab; Bone Density Conservation Agents; Physiological Effects of Drugs